
Alison Kanski
Reporter at Precision Oncology News
Biopharma reporter, Precision Oncology News @PrecOncNews Previously: @MMMnews @PRWeek. Views are mine, but I never tweet.
Articles
-
4 days ago |
precisionmedicineonline.com | Alison Kanski
NEW YORK – Researchers are weighing the efficacy and toxicity of triplet combinations comprising KRAS inhibitors, EGFR inhibitors, and chemotherapy, and considering whether these KRAS inhibitor combinations can move into the first-line setting for colorectal cancer patients based on later-line data.
-
1 week ago |
precisionmedicineonline.com | Alison Kanski
NEW YORK – Survival results from the Phase III DESTINY-Gastric04 trial confirmed that AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Enhertu (trastuzumab deruxtecan; T-DXd) should be the standard second-line treatment for HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer.
-
2 weeks ago |
precisionmedicineonline.com | Alison Kanski
NEW YORK – Researchers are exploring whether an artificial intelligence-based tool can assist pathologists in evaluating HER2 expression by immunohistochemistry (IHC) and improve accuracy when scoring HER2-low and -ultralow breast cancer cases that may benefit from HER2-targeted antibody-drug conjugates.
-
2 weeks ago |
genomeweb.com | Alison Kanski
NEW YORK – Researchers from Mass General Brigham are developing a liquid biopsy whole-genome sequencing assay that could aid in early detection of human papillomavirus (HPV)-associated head and neck cancers. The researchers published a study in Clinical Cancer Research this week, comparing the ability of their assay, called HPV-DeepSeek, to detect head and neck cancer cells in blood against other sequencing methods.
-
3 weeks ago |
precisionmedicineonline.com | Alison Kanski
NEW YORK – An analysis of real-world biomarker testing practices within a US community oncology setting found that about 70 percent of bladder cancer patients received some level of testing. Researchers considered data from nearly 6,000 bladder cancer patients over 10 years and presented their analysis this week at the annual meeting for ISPOR, the professional society for health economics and outcomes research.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 529
- Tweets
- 1K
- DMs Open
- No

RT @TurnaRay: @MassGeneralNews Program to Help Doctors Balance End-of-Life Talks With Precision Oncology Optimism; story by @alisonkanski…

RT @TurnaRay: @StJude Program Installing @nanopore Sequencing in Low-Income Countries to Diagnose Pediatric Blood Cancers; great story by @…

RT @TurnaRay: Come work with me, @Ch_Hops, and @alisonkanski at @PrecOncNews! https://t.co/ImJczGIUon